Роль внутриклеточных протеолитических систем в развитии и прогнозе рака эндометрия
Диссертация
В связи с тем, что социальная значимость РЭ в настоящее время велика, актуальной является также проблема выявления в популяции женщин с высоким онкологическим риском по РЭ, что в конечном итоге представляется адекватным направлением в снижении заболеваемости и смертности от этого заболевания. В первую очередь к этой категории относятся пациентки, страдающие гиперпластическими процессами… Читать ещё >
Содержание
- СПИСОК СОКРАЩЕНИЙ
- ГЛАВА 1. Обзор литературы
- 1. 1. Современные представления о патогенезе рака эндометрия
- 1. 2. Роль убиквитин-протеасомной системы в развитии рака эндометрия
- 1. 2. 1. Характеристика убиквитин-протеасомной системы
- 1. 2. 2. Роль убиквитин-протеасомной системы в патогенезе рака эндометрия
- 1. 3. Роль кальпаинов в развитии рака эндометрия
- 1. 3. 1. Характеристика кальпаиновой системы
- 1. 3. 2. Роль кальпаинов в патогенезе рака эндометрия
- 1. 4. Белки, ассоциированные с клеточной подвижностью, их роль в инвазии и метастазировании и связь с внутриклеточными протеиназами
- 1. 5. Молекулярные маркеры рака эндометрия и онкологического риска при гиперплазии эндометрия
Список литературы
- Активность протеасом в опухолях женской репродуктивной системы / И. В. Кондакова, JI.B. Спирина, Е. Е. Шашова и др. // Биоорганическая химия. 2012. — Т. 38, № 1. — С. 106−111.
- Активность протеасом и их субъединичный состав при раке почки и мочевого пузыря / JI.B. Спирина, И. В. Кондакова, Е. А. Усынин, Н. П. Шарова // Онкоурология. 2010. — № 3. — С. 12−15.
- Берштейн JI.M. Гормональный канцерогенез. — СПб.: Наука, 2000. — 199 с.
- Берштейн JI.M. Эпидемиология, патогенез и пути профилактики рака эндометрия : стабильность или эволюция? // Практическая онкология. — 2004. —Т. 5, № 1. — С. 1−8.
- Бондарева JI.A. Внутриклеточная Са-зависимая протеолитическая система животных / Л. А. Бондарева, H.H. Немова, Е. И. Кяйвяряйнен. М.: Наука, 2006. — 294 с.
- Бочкарева Н.В. Роль актинсвязывающих белков в клеточном движении в норме и при опухолевом росте / Н. В. Бочкарева, И. В. Кондакова, Л. А. Коломиец // Молекулярная медицина. 2011. — № 6 — С.14−18.
- Давыдов А. И Роль лептина в регуляции репродуктивной системы женщины / А. И. Давыдов, М. А. Стрижакова, О. Н. Орлов // Вопросы гинекологии, акушерства и перинатологии. — 2004. Т. 3, № 6. —С. 84−89.
- Доброхотова Ю.Э. Эндохирургические методы лечения предраковых состояний эндометрия / Ю. Э. Доброхотова, М. Г. Бенедиктова, Л.В.
- Сапрыкина // Лечебное дело. — 2010. — № 2. — С. 66−69.
- Иммуногистохимические критерии прогноза при раке эндометрия / A.JI. Чернышова, JI.A. Коломиец, Н. В. Бочкарева, Н. Г. Крицкая // Сибирский онкологический журнал. — 2010. — № 1. — С. 79−84.
- Инсулиноподобные факторы роста и связывающие их белки в патогенезе рака эндометрия / Н. В. Бочкарева, И. В. Кондакова, JI.A. Коломиец, A. JL Чернышова // Сибирский онкологический журнал. — 2008. — № 3. — С. 86−93.
- Каприн А.Д. Состояние онкологической помощи населению России в 2012 году / А. Д. Каприн, В. В. Старинский, Г. В. Петрова. — М.: ФГБУ «МНИОИ им. П.А. Герцена» Минздрава России, 2013. — 232 с.
- Киселев В.И. Роль метаболитов эстрогенов в канцерогенезе репродуктивных органов / В. И. Киселев, E. J1. Мужейник // Акушерство и гинекология. — 2006. — № 3. — С. 1−4.
- Коломиец JI.A. Рак эндометрия и метаболический синдром / JI.A. Коломиец, Н. В. Бочкарева, A.JI. Чернышова. — Томск: Иван Федоров, 2010. —228 с.
- Множественность форм протеасомы и некоторые подходы к их разделению / Е. Б. Абрамова, Т. М. Астахова, П. А. Ерохов, Н. П. Шарова // Известия Российской академии наук. Серия биологическая. 2006. — № 2. -С. 150.
- Московская медицинская академия им. И. М. Сеченова. 2 006 108 570/15- заявл. 20.03.2006- опубл. 20.11.2007.
- Прогнозирование рака тела матки у женщин с гиперпластическими процессами эндометрия в пременопаузальном возрасте / A. J1. Унанян, И. С. Сидорова, Е. А. Коган, Д. В. Бабурин // Акушерство, гинекология и репродукция. -2012. N2. — С. 18−24.
- Прогностические критерии онкологического риска при пролиферативных процессах эндометрия / A.JI. Чернышова, JI.A. Коломиец, Н. Г. Крицкая, И. В. Суходоло // Российский онкологический журнал. 2003. — № 5. — С. 22−25.
- Ровенский Ю.А. Морфогенетические реакции клеток и их нарушения при опухолевой трансформации / Ю. А. Ровенский, Ю. М. Васильев // Канцерогенез. М.: Медицина, 2004. С. 376—414.
- Сорокин A.B. Протеасомная система деградации и процессинга белков / A.B. Сорокин, Е. Р Ким, Л. П. Овчинников // Успехи биологической химиию — 2009. — Т. 49. — С. 3−76.
- Спирина Л.В. Рольвнутриклеточного специфического протеолиза в онкогенезе / Л. В. Спирина, И. В. Кондакова // Вопросы онкологии. —2008. — Т. 54, № 6. — С. 690−694.
- Харитонова Т.В. Рак тела матки / Т. В. Харитонова // Онкогинекология. — 2000.—№ 2. —С. 44−48.
- Цимоха А.С. Протеасомы : участие в клеточных процессах / А. С. Цимоха / Цитология. — 2010. — Т. 52, № 4. — С. 277−300.
- Чиссов В.И. Злокачественные новообразования в России в 2009 году / В. И. Чиссов, В. В. Старинский, Г. В. Петрова. — М.: ФГУ «МНИОИ им. П. А. Герцена Минздравсоцразвития России», 2011. — 260 с.
- Lopatniuk P. Conventional calpains and programmed cell death / P. Lopatniuk, J.M. Witkowski // Acta Biochim Pol. 2011. — Vol. 58, No. 3. — P. 287−96.
- A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice / M. Wehenkel, J.O. Ban, Y.K. Ho, et al. // Br J Cancer. 2012. — Vol. 107, No. 1. -P. 53−62.
- A subset of membrane-associated proteins is ubiquitinated in response to mutations in the endoplasmic reticulum degradation machinery / A.L. Hitchcock, K. Auld, S.P. Gygi, P.A. Silver // Proc Natl Acad Sci USA.- 2003. -Vol. 100(22).-P. 12 735−40.
- Abe K. NMDA-receptor activation induces calpain-mediated beta-catenincleavages for triggering gene expression / K. Abe, M. Takeichi // Neuron. 2007. — Vol. 53, No.3. — P. 387−97.
- Actin binding proteins: regulation of cytoskeletal microfilaments / C. G dos Remedios, D. Chhabra, M. Kekic, et al. // Physiol Rev. 2003. — Vol. 83, No. 2.-P. 433−73.
- Almond J.B. The proteasome: a novel target for cancer chemotherapy / J.B. Almond, GM. Cohen // Leukemia. — 2002. — Vol. 16. — P. 433−443.
- Anti-breast cancer effects of histone deacetylase inhibitors and calpain inhibitor / M.A. Mataga, S. Rosenthal, S. Heerborth, et al. // Anticancer Res. -2012. Vol. 32, No. 7. — P. 2523−9.
- APC, (3-catenin, and E-cadherin and the development of recurrent endometrialcarcinoma / J.M.A. Pijnenborg, N. Kisters, M. Van Engeland, et al. //1.ternational Journal of Gynecological Cancer. 2004. — Vol.14 (5). — P. 947 956.
- ASB2 targets filamins A and B to proteasomal degradation / M.L. Heuze, I. Lamsoul, M. Baldassare, et al. // Blood. — 2008. — Vol. 112, No. 13. — P. 5130−40.
- Asher G p53 proteasomal degradation: poly-ubiquitination is not the whole story / G Asher, Y. Shaul // Cell Cycle. 2005. — Vol. 4(8). — P. 1015.
- Bender D. Hormones and receptors in endometrial cancer / D. Bender, T. Buekers, K.K. Leslie // Proceedings in Obstetrics and Gynecology. — 2011. — Vol. 2, No. 1.—P. 1−25.
- Beta-catenin mutations and aberrant nuclear expression during endometrial tumorigenesis / M. Saegusa, M. Hashimura, T. Yoshida, I. Okayasu // Br J Cancer. — 2001. — Vol. 84, No. 2. — P. 209−17.
- Bienz M. Linking colorectal cancer to Wnt signaling / M. Bienz, H. Clevers // Cell. -2000. Vol. 103(2). — P. 311−20.
- Bioinformatic analysis of functional differences between the immunoproteasome and the constitutive proteasome / C. Kesmir, V. van Noort, R.J. de Boer, P. Hogeweg // Immunogenetics. 2003. — Vol. 55, No. 7. — P. 437−49.
- Bortezomib (Velcade) induces p27Kipl expression through S-phase kinase protein 2 degradation in colorectal cancer / S. Uddin, M. Ahmed, P. Bavi, et al. // Cancer Res. 2008. — Vol.68. — No. 9. — P. 3379−88.
- Ca 2±dependent neutral protease (Calpain) activity in breast cancer tissue and estrogen receptor status / E. Shiba, J.-I. Kambayashi, M. Sakon, et al. // Breast Cancer. 1996. — Vol. 3, Issue 1. -P. 13−17.
- Calpain 2 regulates Akt-FoxO-p27(Kipl) protein signaling pathway in mammary carcinoma / W.C. Ho, L. Pikor, Y. Gao, et al. // J Biol Chem. 2012. -Vol. 287(19). — P. 15 458−65.
- Calpain as a multi-site regulator of cell cycle / J. Janossy, P. Ubezio, A. Apati, et al. // Biochem Pharmacol. 2004. — Vol. 67, No. 8. — P. 1513−21.
- Calpain inhibitor 1 activates p53-dependent apoptosis in tumor cell lines / I.A. Atencio, M. Ramachandra, P. Shabram, GW. Demers // Cell Growth Differ. -2000.-Vol. 11, No. 5.-P. 247−53.
- Calpain system protein expression in basal-like and triple-negative invasivebreast cancer / S.J. Storr, K.W. Lee, C.M. Woolston, et al. // Ann Oncol. -2012. Vol. 23(9). — P. 2289−96.
- Calpain-1 expression is associated with relapse-free survival in breast cancer patients treated with trastuzumab following adjuvant chemotherapy / S.J. Storr, C.M. Woolston, F.F. Barros, et al. // Int J Cancer. 2011. — Vol. 129, No. 7. — P. 1773−80.
- Calpain-2 expression is associated with response to platinum basedchemotherapy, progression-free and overall survival in ovarian cancer / S.J. Storr, S. Safuan, C.M. Woolston, et al. // J Cell Mol Med. 2012. — Vol. 16, No. 10.-P. 2422−8.
- Calpain-2 regulation of VEGF-mediated angiogenesis / Y. Su, Z. Cui, Z. Li, E.R. Block//ASEB J. 2006. — Vol. 20, No. 9. — P. 1443−51.
- Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome / F. Parlati, S.J. Lee, M. Aujay, et al. // Blood. 2009. — Vol. 114. — P. 3439−3447 .
- Carragher N. O. Calpain activity is generally elevated during transformation but has oncogene-specific biological functions / N.O. Carragher, B.D. Fonseca, M.C. Frame // Neoplasia. — 2004. — Vol. 6. — P. 53−73.
- Carragher N.O. Calpain: a role in cell transformation and migration / N.O. Carragher, M.C. Frame // Int J Biochem Cell Biol. 2002. — Vol. 34(12). — P. 1539−43.
- Caspase-mediated cleavage of beta-catenin precedes drug-induced apoptosis in resistant cancer cells / S. Senthivinayagam, P. Mishra, S.K. Paramasivam, et al. // J Biol Chem. 2009. — Vol. 284(20). — P. 13 577−88.
- Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma / J. Madore, F. Ren, A. Filali-Mouhim, et al. // J Pathol. 2010. — Vol. 220, No. 3. — P. 392−400.
- Christiansen J.J. Reassessing Epithelial to Mesenchymal Transition as a Prerequisite for Carcinoma Invasion and Metastasis / J.J. Christiansen, A.K.
- Rajasekaran // Cancer Res. 2006. — Vol. 66. — P. 8319.
- Cleavage of beta-catenin by calpain in prostate and mammary tumor cells / J. Rios-Doria, R. Kuefer, S.P. Ethier, M.L. Day // Cancer Res. 2004. — Vol. 64, No. 20.-P. 7237−40.
- Clevers H. Wnt/beta-catenin signaling in development and disease // Cell. — 2006. — Vol. 127, No. 3. — P. 469−480.
- Comparative proteomic approach identifies PKM2 and cofilin-1 as potential diagnostic, prognostic and therapeutic targets for pulmonary adenocarcinoma / X.C. Peng, F.M. Gong, Y.W. Zhao, et al. // PLoS One. 2011. — Vol. 6(11). -e27309.
- CUE domain containing 2 regulates degradation of progesterone receptor by ubiquitin-proteasome / P.J. Zhang, J. Zhao, H.Y. Li, et al. // EMBO J. — 2007. — Vol. 26.—P. 1831−42.
- Deletion analysis of BMI1 oncoprotein identifies its negative regulatory domain / A.K. Yadav, A.A. Sahasrabuddhe, M. Dimri, et al. // Molecular Cancer. -2010. Vol. 9. — P. 158.
- Delia Donna L. Radioresistance of prostate cancer cells with low proteasome activity / L. Delia Donna, C. Lagadec, F. Pajonk // Prostate. 2012. — Vol. 72,1. No. 8.-P. 868−74.
- Deregulated intracellular signaling by mutated c-CBL in myeloid neoplasms / S. Ogawa, L.-Y. Shih, T. Suzuki, et al. // Clinical Cancer Research. — 2010. — Vol. 16. —P. 3825−31.
- DeWard A.D. Ubiquitin-mediated degradation of the formin mDia2 uponcompletion of cell division / A.D. DeWard, A.S. Alberts // JBC. 2009. — Vol. 284. — No. 30. — P. 20 061−69.
- Diagnostic and prognostic significance of miRNA signatures in tissues and plasma of endometrioid endometrial carcinoma patients / A. Torres, K. Torres, A. Pesci, et al. // Int J Cancer. 2013. — Vol. 132, No. 7. — P. 1633−45.
- Differential actions of estrogen and SERMs in regulation of the actin cytoskeleton of endometrial cells / M.I. Flamini, A.M. Sanchez, L. Goglia, et al. // Mol Hum Reprod. 2009. — Vol. 15(10). — P. 675−85.
- Diminished feedback regulation of proteasome expression and resistance to proteasome inhibitors in breast cancer cells / H. Xu, D. Ju, T. Jarois, Y. Xie // Breast Cancer Res Treat. — 2008. — Vol. 107, No. 2. — P. 267−74.
- Donkor I.O. Calpain inhibitors: a survey of compounds reported in the patent and scientific literature / I.O. Donkor // Expert Opin Ther Pat. — 2011. — Vol. 21, No. 5.—P. 601−36.
- Down-regulation of the transporter for antigen presentation, proteasomesubunits, and class I major histocompatibility complex in tumor cell lines / A. Johnsen, J. France, M.S. Sy, C.V. Harding // Cancer Res. 1998. — Vol. 58, No.16.-P. 3660−7.
- Downregulation of gelsolin family proteins counteracts cancer cell invasion in vitro / A. Van den Abbeele, V. De Corte, K. Van Impe, et al. // Cancer Lett. -2007. Vol. 255, No. 1. — P. 57−70.
- DuVerle D.A. Calpain cleavage prediction using multiple kernel learning / D.A. DuVerle, H. Sorimachi, H. Mamitsuka // PLoS One. 2011. — Vol. 6, No. 5. — el9035.
- Elevated calpain activity in acute myelogenous leukemia correlates with decreased calpastatin expression / M. Niapour, C. Farr, M. Minden, S.A. Berger // Blood Cancer J. 2012. — Vol. 2, No. 1. — e51.
- Emerging roles of immunoproteasomes beyond MHC class I antigen processing / F. Ebstein, P.M. Kloetzel, E. Kriiger, U. Seifert // Cell Mol Life Sci. — 2012. — Vol. 69, No. 15. — P. 2543−58.
- Endometrial carcinoma risk among women diagnosed with endometrial hyperplasia: the 34-year experience in a large health plan / J.V. Lacey, Jr, O.B. Ioffe, B.M. Ronnett, et al. // Br J Cancer. — 2008. — Vol. 98, No. 1. — P. 4553.
- Engelsen I.B. Biologic markers in endometrial cancer treatment / I.B.
- Engelsen, L.A. Akslen, H.B. Salvesen //APMIS. 2009. — Vol. 117, No. 10. -P. 693−707.
- Epithelial Membrane Protein-2 Expression is an Early Predictor of Endometrial Cancer Development / O. Habeeb, L. Goodglick, R.A. Soslow, et al. // Cancer. — 2010. — Vol. 116, No. 20. — P. 4718^1726.
- Estrogen and Progesterone Regulate p27kipl Levels via the Ubiquitin
- Proteasome System: Pathogenic and Therapeutic Implications for Endometrial Cancer / K.T. Huang, S.C. Pavlides, J. Lecanda, et al. // PLoS One. 2012. -Vol. 7. — e46072.
- Estrogen binding proteins of calf uterus. Molecular and functional characterization of the receptor transforming factor: A Ca2±activated protease / GA. Puca, E. Nola, V. Sica, F. Bresciani // J Biol Chem. 1977. — Vol. 252(4).-P. 1358−66.
- Estrogen regulates endometrial cell cytoskeletal remodeling and motility via focal adhesion kinase / M.I. Flamini, A.M. Sanchez, A.R. Genazzani, T. Simoncini // Fertil Steril. 2011. — Vol. 95, No. 2. — P. 722−6.
- Expression of the calpain system is associated with poor clinical outcome ingastro-oesophageal adenocarcinomas / S.J. Storr, X. Pu, J. Davis, et al. // J Gastroenterol. 2013. — Epub ahead of print.
- Gadducci A. Tissue and serum biomarkers as prognostic variables in endometrioid-type endometrial cancer / A. Gadducci, S. Cosio, A.R. Genazzani // Crit Rev Oncol Hematol. 2011. — Vol. 80, No. 2. — P. 181 -92.
- Gelsolin as a negative prognostic factor and effector of motility in erbB-2-positive epidermal growth factor receptor-positive breast cancers / A.D. Thor, S.M. Edgerton, S. Liu S, et al. // Clin Cancer Res. 2001. — Vol. 7, No. 8. — P. 2415−24.
- Gelsolin-induced epithelial cell invasion is dependent on Ras-Rac signaling / V. De Corte, E. Bruyneel, C. Boucherie, et al. // EMBO J. 2002. — Vol. 21, No. 24.-P. 6781−90.
- Genotypic and phenotypic progression in endometrial tumorigenesis: determining when defects in DNA mismatch repair and KRAS2 occur / D.E. Cohn, D. G Mutch, T.J. Herzog et al. // Genes Chromosomes Cancer. — 2001.
- Vol. 32, No.4. — P. 295−301.
- Glasgow E., Transforming growth factor-beta signaling and ubiquitinators in cancer / E. Glasgow, L. Mishra // Endocrine-Related Cancer. 2008. — Vol. 15.- P. 59−72.
- Hanahan D. The hallmarks of cancer / D. Hanahan, RA. Weinberg // Cell. — 2000. — Vol. 100(1). — P. 57−70.
- Hayashi T. Development of spontaneous uterine tumors in low molecular masspolypeptide-2 knockout mice / T. Hayashi, D.L. Faustman // Cancer Res. 2002. Vol. 62, No. 1. — P. 24−7.
- HE4 is an independent prognostic marker in endometrial cancer patients / I. Mutz-Dehbalaie, D. Egle, S. Fessler, et al. // Gynecol Oncol. 2012. — Vol. 126, No. 2.-P. 186−91.
- High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma / D.A. Garcia-Dios, D. Lambrechts, L. Coenegrachts, et al. // Gynecol Oncol. 2013. — Vol. 128, No. 2.-P. 327−34.
- Hypoxia-Inducible Factor-1 as a Therapeutic Target in Endometrial Cancer Management / L.M.S. Seeber, R. P Zweemer, R.H.M. Verheijen, P.J. van Diest // Obstet Gynecol Int. 2010. — Vol.2010: 580 971.
- Identification of c-MYC as a target of the APC pathway / T.C. He, A.B. Sparks, C. Rago, et al. // Science. 1998. — Vol. 281, No. 5382. — P. 1509−12.
- Identification of calpain cleavage sites in the G1 cyclin-dependent kinase inhibitor pl9(INK4d) / J. Joy, N. Nalabothula, M. Ghosh, et al. // Biol Chem. -2006. Vol. 387, No. 3. — P. 329−35.
- Identification of platinum-resistance associated proteins through proteomicanalysis of human ovarian cancer cells and their platinum-resistant sublines / X.D. Yan, L.Y. Pan, Y. Yuan, et al. // J Proteome Res. — 2007. — Vol. 6(2). — P. 772−80.
- Immunhistochemical analysis for expression of calpainl, calpain 2 and calpastatin in endometrial cancer / D. Salehin, I. Fromberg, C. Haugk, et al. // Anticancer Res. — 2010. — Vol. 30, No. 7. — P. 2837−43.
- Immunohistochemical expression of cyclin E in endometrial adenocarcinoma (endometrioid type) and its clinicopathological significance / N. Kato, J. Watanabe, T. Jobo, et al. // J Cancer Res Clin Oncol. 2003. — Vol. 129, No. 4.-P. 222−6.
- Impaired expression of proteasome subunits and human leukocyte antigens class I in human colon cancer cells / T. Miyagi, T. Tatsumi, T. Takehara, et al. // J Gastroenterol Hepatol. 2003. — Vol. 18, No. 1. — P. 32−40.
- Inhibition of proteasome activity induces concerted expression of proteasome genes and de novo formation of Mammalian proteasomes / S. Meiners, D. Heyken, A. Weller, et al. // J Biol Chem. 2003. — Vol. 278, No. 24.-P. 21 517−25.
- Inhibition of the 26S proteasome blocks progesterone receptor-dependent transcription through failed recruitment of RNA polymerase II / A.P. Dennis, D.M. Lonard, Z. Nawaz, B.W. O’Malley // J Steroid Biochem Mol Biol. — 2005. — Vol. 94. — P. 337−46.
- Insulin-like growth factor-2 (IGF-2) activates estrogen receptor-a and -(3 via the IGF-1 and the insulin receptors in breast cancer cells / A.E. Richardson, N. Hamilton, W. Davis // Growth Factors. — 2011. — Vol. 29. — P. 82−93.
- Integrated genomic characterization of endometrial carcinoma / The Cancer Genome Atlas Research Network // Nature. — Vol. 497. — P. 67−73.
- Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells / B. Shi, J. Liang, X. Yang, et al. // Mol Cell Biol. — 2007. — Vol. 27. — P. 5105−19.
- Involvement of 26S proteasome in the invasion of human cytotrophoblast cells during early pregnancy / C. Zhu, J. Fu, P. Lin, et al. // Biology of Reproduction. 2008. — Vol. 78. — P. 143.
- Involvement of Arp2/3 complex in the process of colorectal carcinogenesis / T. Otsubo, K. Iwaya, Y. Mukai, et al. // Mod Pathol. — 2004. — Vol. 17(4). — P. 461−7.
- Involvement of proteasome (31i subunit, LMP2, on development of uterin leiomyosarcma / T. Hayashi, A. Horiuchi, K. Sano, et al. // N Am J Med Sci. -2011.-Vol. 3, No. 9.-P. 394−9.
- Jung T. Structure of the proteasome / T. Jung, T. Grune // Prog Mol Biol Transl Sci. — 2012. — Vol. 109. — P. 1−39.
- Kaaks R. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review / R. Kaaks, A. Lukanova, M.S. Kurzer // Cancer Epidemiol Biomarkers Prev. — 2002. — Vol. 11, No. 12. — P. 1531−43.
- Keshamouni V. G Epithelial-mesenchymal transition in tumor metastasis: a method to the madness / V. G Keshamouni, W.P. Schiemann // Future Oncol. -2009. Vol. 5(8). — P. 1109−11.
- Kisselev A.F. Proteasome inhibitors: an expanding army attacking a unique target / A.F. Kisselev, W.A. van der Linden, H.S. Overkleeft // Chemistry & Biology. 2012. — Vol. 19. — P. 99−115.
- Kitagawa K. Ubiquitin-mediated control of oncogene and tumor suppressor gene products / K. Kitagawa, Y. Kotake, M. Kitagawa // Cancer Science. — 2009.— Vol. 100, No. 8. —P. 1374—1381.
- Lambrechts A. The actin cytoskeleton in normal and pathological cellmotility / A. Lambrechts, M. Van Troys, C. Ampe // Int J Biochem Cell Biol. — 2004.—Vol. 36, No. 10. —P. 1890−909.
- Larsson L.I. Occurrence of thymosin beta4 in human breast cancer cells and in other cell types of the tumor microenvironment / L.I. Larsson, S. Hoick // Hum Pathol-2007.-Vol. 38.-P. 114−119.
- Leloup L. Calpains as potential anti-cancer targets / L. Leloup, A. Wells //
- Expert Opin Ther Targets. 2011. — Vol. 15. — P. 309−23.
- Levina E Downregulation of beta-catenin by p53 involves changes in the rate of beta-catenin phosphorylation and Axin dynamics / E. Levina, M. Oren, A. Ben-Ze'ev // Oncogene. 2004. — Vol. 23(25). — P. 4444−53.
- Live-cell imaging of tumor proteolysis: Impact of cellular and non-cellularmicroenvironment / J.M. Rothberg, M. Sameni, K. Moin, B.F. Sloane // Biochimica et Biophysica Acta. 2012. — Vol.1824. — R 123−132.
- Lu Z. Degradation of activated protein kinases by ubiquitination / Z. Lu, T. Hunter //Annu Rev Biochem. 2009. — Vol. 78. — P. 435−475.
- MALAT-1 a novel noncoding RNA and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer / P. Ji, S. Diederichs, W. Wang, et al. // Oncogene. 2003. — Vol. 22. — P. 6087−6097.
- MAP kinase-dependent degradation of p27Kipl by calpains in choroidalmelanoma cells. Requirement of p27Kipl nuclear export / C. Delmas, N. Aragou, S. Poussard, et al. // J Biol Chem. 2003. — Vol. 278, No. 14. — P. 12 443−51.
- Meulmeester E. The dynamic roles of TGF-0 in cancer / E. Meulmeester, P. ten Dijke // The Journal of Pathology. 2011. — Vol. 223. — Issue 2. — P. 206
- MHC class I molecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells / C. Garrido, L. Paco, I. Romero, et al. // Carcinogenesis. 2012. — vol.0. -P. 1−7.
- Molecular mechanisms involved in activity of h7C10, a humanized monoclonal antibody, to IGF-1 receptor / M. Broussas, J. Dupont, A. Gonzalez, et al. // Int. J. Cancer, — 2009. — Vol. 124. — P. 2281−2293.
- Molecular regulation of immunoproteasome overexpression in papillary thyroid carcinoma / X. Zhang, Q. Du, W. Gao, M.T. Stang // Abstracts of The Academic Surgical Congress. New Orleans, Feb. 5−7, 2013.
- Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias / GL. Maxwell, J.I. Risinger, C. Gumbs, et al. // Cancer Res. — 1998. — Vol. 58, No. 12.—P. 2500−3.
- Mutter GL Molecular pathogenesis of endometrial cancer / GL. Mutter, T.A. Ince // Uterine Cancer: American Cancer Society Atlas of Clinical Oncology. — Hamilton, Ontario, Canada: B.C.Decker, 2003.
- Natural proteasome inhibitor celastrol suppresses androgen-independentprostate cancer progression by modulating apoptotic proteins and NF-kappaB / Y. Dai, J. Desano, W. Tang, et al. // Br J Haematol. — 2011. — Vol. 153(2). — P. 222−35.
- Negative regulation of 26S proteasome stability via calpain-mediated cleavage of RpnlO subunit upon mitochondrial dysfunction in neurons / Q. Huang, H. Wang, S.W. Perry, M.E. Figueiredo-Pereira // J Biol Chem. 2013. -Vol. 288, No. 17. — P. 12 161−74.
- O’Hara A.J. The genomics and genetics of endometrial cancer / A.J. O’Hara, D.W. Bell //Adv Genomics Genet. — 2012. — Vol. 2012(2). — P. 33−47.
- Overexpression of gelsolin in human cervical carcinoma and its clinicopathological significance / C.J. Liao, T.I. Wu, Y.H. Huang, et al. // Gynecol Oncol. 2011. — Vol. 120, No. 1. — 135−44.
- Overexpression of m-calpain in human colorectal adenocarcinomas / A. Lakshmikuttyamma, P. Selvakumar, R. Kanthan, et al. // Cancer Epidemiol. Biomarkers Prev. 2004. — Vol. 13, No. 10. — P. 1604−9.
- Overexpression of MMSET in endometrial cancer: a clinicopathologic study / M. Xiao, S. Yang, J. Chen, et al. // J Surg Oncol. 2013. — Vol. 107, No. 4. -P. 428−32.
- P53-independent pRB degradation contributes to a drug-induced apoptosis in AGS cells / Y. Jin, W.K. Leung, J.J. Sung, J.R. Wu // Cell Research. 2005. -Vol. 15.-P. 695−703.
- Pakl/LIMKl/Cofilin Pathway Contributes to Tumor Migration and Invasion in Human Non-Small Cell Lung Carcinomas and Cell Lines / I. Jang, B.T. Jeon, E.A. Jeong, et al. // Korean J Physiol Pharmacol. 2012. — Vol. 16(3). -P. 159−65.
- Park B.-K. Aktl induces extracellular matrix invasion and matrix metalloproteinase-2 activity in mouse mammary epithelial cells / B.-K. Park, X. Zeng, R.I. Glazer // Cancer Res. 2001. — Vol. 61. — P. 7647.
- Petroski M.D. The ubiquitin system, disease, and drug discovery / M.D. Petroski // BMC Biochemistry. — 2008. — Vol. 9(Suppl 1): S7 doi: 10.1186/1471 -2091 -9-S1-S7.
- Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase / S. Taurin, N. Sandbo, Y. Qin, et al. // J Biol Chem. 2006. — Vol. 281(15). — P.9971−6.
- PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia / M.P. Hayes, H. Wang, R. Espinal-Witter // Clin Cancer Res. — 2006. — Vol. 12. — P. 5932−5.
- Plataniotis G Endometrial cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up / G Plataniotis, M. Castiglione // Annals of Oncology.- 2010. Vol. 21 (Supplement 5). — P. 4115.
- Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologistsrecommendations / R. Salani, F.J. Backes, M.F. Fung, et al. // Am J Obstet
- Gynecol. 2011. — Vol. 204, No. 6. — P. 466−78.
- Potential roles for PA28beta in gastric adenocarcinoma development and diagnosis / Q. Huang, Q. Huang, W. Lin, et al. // J Cancer Res Clin Oncol. -2010. Vol. 136, No. 8. — P. 1275−82.
- PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo / A.V. Singh, M. Bandi, M.A. Aujay, et al. // Br J Haematol. 2011. — Vol. 152, No. 2. — P. 15 563.
- Predicting the risk of endometrial cancer in postmenopausal women presenting with vaginal bleeding: the Norwich DEFAB risk assessment tool / N. Burbos, P. Musonda, I. Giarenis, et al. // Br J Cancer. — 2010. — Vol. 102, No. 8.—P. 1201−1206.
- Pretreatment serum levels of bFGF and VEGF and its clinical significance in endometrial carcinoma / B. Dobrzycka, B. Mackowiak-Matejczyk, M. Kinalski, S.J. Terlikowski // Gynecol Oncol. 2013. — Vol. 128. — P. 454−60.
- Progesterone receptor isoform identification and subcellular localization in endometrial cancer / K.K. Leslie, M.P. Stein, N.S. Kumar, et al. // Gynecol Oncol. — 2005. — Vol. 96. — P. 32−41.
- Prognostic significance of VEGF and its receptors in endometrioid endometrial cancer / B. Dobrzycka, S.J. Terlikowski, M. Kwiatkowski, et al. // Ginekol Pol. 2010. — Vol. 81, No. 6. — P. 422−5.
- Progression of cancer from indolent to aggressive despite antigen retention and increased expression of interferon-gamma inducible genes / T.H. Wu, K. Schreiber, A.A. Arina et al. // Can Immun. 2011. — Vol. 11. — P. 2.
- Proteasome beta-type subunits: unequal roles of propeptides in core particle maturation and a hierarchy of active site function / S. Jager, M. Groll, R. Huber, et al. // J Mol Biol. — 1999. — Vol. 291, No. 4. — P. 997−1013.
- Proteasome inhibitor lactacystin augments natural killer cell cytotoxicity of myeloma via downregulation of HLA class I / X. Wu, Y. Shao, Y. Tao, et al. // Biochem Biophys Res Commun. 2011. — Vol. 415, No. 1. — P. 187−92.
- Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB (alpha) degradation / C. Li, S. Chen, P. Yue, et al. // J Biol Chem. — 2010. — Vol. 285, No. 21. — P. 16 096−104.
- Proteasome inhibitors induce death but activate NF-kappaB on endometrial carcinoma cell lines and primary culture explants / X. Dolcet, D. Llobet, M. Encinas, et al. // J Biol Chem. 2006. — Vol. 281. — P. 22 118−30.
- Proteasome subunit LMP2 is required for matrix metalloproteinase-2 and -9 expression and activities in human invasive extravillous trophoblast cell line / H.X. Wang, H.M. Wang, H.Y. Lin, et al. // J Cell Physiol. — 2006. — Vol. 206. — P. 616−23.
- Rahimi N. A role for protein ubiquitination in VEGFR-2 signalling and angiogenesis / N. Rahimi // Biochem. Soc. Trans. 2009. — Vol.37. — P. 118 993.
- Role of the cofilin activity cycle in astrocytoma migration and invasion / S. Nagai, O. Moreno, C.A. Smith, et al. // Genes Cancer. 2011. — Vol. 2(9). — P. 859−69.
- Saitoh M. Regulation of the stability of cell surface E-cadherin by the proteasome / M. Saitoh, T. Shirakiharaa, K. Miyazono // Biochemical and Biophysical Research Communications. 2009. — Vol.381. — Issue 4. — P. 560
- Samarnthai N. Molecular profiling of endometrial malignancies / N. Samarnthai, K. Hall, I-T. Yeh // Obstet Gynecol Int. — 2010. — Vol. 2010: 162 363.
- SerpinB2 protection of retinoblastoma protein from calpain enhances tumor cell survival / L. Tonnetti, S. Netzel-Arnett, GA. Darnell, et al. // Cancer Res. -2008. Vol. 68, No. 14. — P. 5648−57.
- Smith I.J. Calpain activation causes a proteasome-dependent increase in protein degradation and inhibits the Akt signalling pathway in rat diaphragm muscle / I.J.Smith, S.L. Dodd // Exp Physiol. 2007. — Vol. 92, No. 3. — P. 561−73.
- Sorimachi H. Calpain chronicle—an enzyme family under multidisciplinary characterization / H. Sorimachi, S. Hata, Y. Ono // Proc Jpn Acad Ser B Phys Biol Sci. 2011. — Vol. 87, No. 6. — P. 287−327.
- Sorimachi H. Expanding members and roles of the calpain superfamily and their genetically modified animals / H. Sorimachi, S. Hata, Y. Ono // Exp Anim. 2010. — Vol. 59, No. 5. — P. 549−66.
- Sorimachi H. Understanding the substrate specificity of conventional calpains / H. Sorimachi, H. Mamitsuka, Y. Ono // Biol Chem. 2012. — Vol. 393(9).-P. 853−71.
- Stadtmueller B.M. Proteasome activators / B.M. Stadtmueller, C.P. Hill // Mol Cell. —2011, —Vol. 41.—P. 8−19.
- Stathmin is superior to AKT and phospho-AKT staining for the detection of phosphoinositide 3-kinase activation and aggressive endometrial cancer / J. Trovik, E. Wik, I. Stefansson, et al. // Histopathology. 2010. — Vol. 57, No. 4. -P. 641−6.
- Structure, activation, and biology of calpain / K. Suzuki, S. Hata, Y. Kawabata, H. Sorimachi // Diabetes. 2004. — Vol. 53 Suppl 1. — P. 12−18.
- Surmacz E. Role of estrogen receptor alpha in modulating IGF-I receptor signaling and function in breast cancer / E. Surmacz, M. Bartucci // J Exp Clin Cancer Res. — 2004. — Vol. 23, No. 3. — P. 385−94.
- Systems microscopy approaches to understand cancer cell migration and metastasis / S.E. Le Devedec, K. Yan, H. de Bont, et al. // Cell Mol Life Sci. -2010. Vol. 67, No. 19. — P. 3219−40.
- Tanaka K. The proteasome: overview of structure and functions / K. Tanaka // Proc Jpn Acad Ser B Phys Biol Sci. — 2009. — Vol. 85. — P. 12−36.
- Targeting the tumor proteasome as a mechanism to control the synthesis and bioactivity of matrix macromolecules / S.S. Skandalis, A.J. Aletras, C. Gialeli, et al. // Curr Mol Med. 2012. — Vol. 12. — P. 1068−82.
- Terry K. MDM2 SNP309 is associated with endometrial cancer risk / K. Terry, M. McGrath, I.-M. Lee // Cancer Epidemiol Biomarkers Prev. 2008. -Vol.17.-P. 983−986.
- Tetraspanin CD151 is a novel prognostic marker in poor outcome endometrial cancer / M.A. Voss, N. Gordon, S. Maloney, et al. // Br J Cancer.2011.-Vol. 104, No. 10.-P. 1611−8.
- Tetsu O. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells / O. Tetsu, F. McCormick // Nature. 1999. — Vol. 398, No. 6726. — P. 422−6.
- TGFbeta prevents proteasomal degradation of the cyclin-dependent kinase inhibitor p27kipl for cell cycle arrest / J. Lecanda, V. Ganapathy, C. D’Aquino-Ardalan, et al. // Cell Cycle. 2009. — Vol. 8(5). — P. 742−756.
- TGF? signaling supports survival and metastasis of endometrial cancer cells / X.F. Lei, L. Wang, J. Yang, L.-Z. Sun // Cancer Management and Research. -2009.-Vol. l.-P. 15−24.
- The actin propulsive machinery: the proteome of Listeria monocytogenes tails / M. VanTroys, A. Lambrechts, V. David, et al. // Biochem Biophys Res Commun. — 2008. — Vol. 375, No. 2. — P. 194−199.
- The calpain system / D.E. Goll, V.F. Thompson, H. Li, et al. // Physiol Rev. -2003.-Vol. 83.-P. 731−801.
- The calpain system and cancer / S.J. Storr, N.O. Carragher, M.C. Frame, et al. //Nature Reviews Cancer. 2011. — Vol. 11. — P. 364−374.
- The calpain system is involved in the constitutive regulation of beta-catenin signaling functions / R. Benetti, T. Copetti, S. Dell’Orso, et al. // J Biol Chem. -2005. Vol. 280, No. 23. — P. 22 070−80.
- The calpain/calpastatin system has opposing roles in growth and metastaticdissemination of melanoma / Q. Raimbourg, J. Perez, S. Vandermeersch, et al. // PLoS ONE. 2013. — Vol. 8(4). — e60469.
- The cancer degradome: proteases in cancer biology / D. Edwards, G Hoyer-Hansen, F. Blasi, B.F. Sloane. — Springer, 2008. — 1000 p.
- The E-cadherin repressor snail plays a role in tumor progression of endometrioid adenocarcinomas / K. Blechschmidt, E. Kremmer, R. Hollweck, et al. // Diagn Mol Pathol. 2007. — Vol. 16(4). — PP. 222−228.
- The expression of syndecan-1 is related to the risk of endometrial hyperplasia progressing to endometrial carcinoma / H. Kim, D.S. Choi, S.J. Chang, et al. // J Gynecol Oncol. 2010. — Vol. 21, No. 1. — P. 50−5.
- The immunoproteasome subunit LMP2 as a novel therapeutic target for non-small cell lung cancer / M. Wehenkel, E.R. Jang, K. Cornish, et al. // American Association of Cancer Research Annual Meeting 2011, Orlando, FL- 04/2011.
- The motility of glioblastoma tumour cells is modulated by intracellular cofilin expression in a concentration-dependent manner / C.T. Yap, T.I. Simpson, T. Pratt, et al. // Cell Motil Cytoskeleton. 2005. — Vol. 60, No. 3. -P. 153−65.
- The p53 tumor suppressor is stabilized by inhibitor of growth 1 (ING1) by blocking polyubiquitination / S. Thalappilly, X. Feng, S. Pastyryeva, et al. // PLoS One.-2011.-Vol. 6.-e21065.
- The ubiquitin proteasome pathway (UPP) in the regulation of cell cycle control and DNA damage repair and its implication in tumorigenesis / Y. Tu, C. Chen, J. Pan, et al. // Int J Clin Exp Pathol. 2012. — Vol. 5, No. 8. — P. 726 738.
- The ubiquitin-proteasome pathway mediates gelsolin protein downregulation in Pancreatic Cancer / X.-G Ni, L. Zhou, G-Q. Wang, et al. // Mol Med. — 2008. — Vol. 14. — P. 582−589.
- The ubiquitin-proteasome protein degradation pathway as a therapeutic strategy in the treatment of solid tumor malignancies / J.J. Driscoll, A. Minter, D.A. Driscoll, J.L. Burns // Anticancer Agents Med Chem. 2011. — Vol. 11, No. 2.-P. 242−246.
- Thymosin beta4 triggers an epithelial-mesenchymal transition in colorectal carcinoma by upregulating integrin-linked kinase / H.C. Huang, C.H. Hu, M.C. Tang, et al. // Oncogene.- 2007. Vol. 26(19). — P. 2781−90.
- Thymosin ?4 in colorectal cancer is localized predominantly at the invasion front in tumor cells undergoing epithelial mesenchymal transition / S. Nemolato, A. Restivo, T. Cabras, et al. // Cancer Biol Ther. 2012. — Vol. 13. -P. 191−197.
- Toward an integrated structural model of the 26S proteasome / F. Forster, K. Lasker, S. Nickell et al. // Mol Cell Proteomics. — 2010. — Vol. 9, No. 8. — P. 1666−77.
- Transforming growth factor-beta, estrogen, and progesterone converge on the regulation of p27Kipl in the normal and malignant endometrium / J. Lecanda, T.V. Parekh, P. Gama, et al. // Cancer Res. 2007. — Vol. 67. — P. 1007−18.
- Ubiquitous calpains promote both apoptosis and survival signals in response to different cell death stimuli / Y. Tan, C. Wu, T. De Veyra, P.A. Greer // J Biol Chem. -2006. Vol. 281. — P. 17 689−98.
- Uharcek P. Prognostic factors in endometrial carcinoma / P. Uharcek // J Obstet Gynaecol Res. — 2008. — Vol. 34, No. 5. — P. 776−83.
- Vascular markers CD31, CD34, actin, VEGFB, and VEGFR2, are prognosticmarkers for malignant development in benign endometrial polyps / B. Hvingel, M. Lieng, B. Roald, A. 0rbo // Open Journal of Obstetrics and Gynecology. 2012.-Vol. 2.-P. 18−26.
- Voutsadakis I.A. The ubiquitin-proteasome system and signal transduction pathways regulating Epithelial Mesenchymal transition of cancer / I.A. Voutsadakis // Journal of Biomedical Science. 2012. — Vol. 19. — P. 67.
- Wagner J. Estrogens modulate the gene expression of Wnt-7a in cultured endometrial adenocarcinoma cells / J. Wagner, L. Lehmann // Mol Nutr Food Res. — 2006. — Vol. 50. — P. 368−72.
- Wnt/p-catenin and sex hormone signaling in endometrial homeostasis and cancer / Y. Wang, M. van der Zee, R. Fodde, L.J. Blok // Oncotarget. — 2010. — Vol. 1(7). —P. 674−684.
- Xie Y. Structure, assembly and homeostatic regulation of the 26Sproteasome / Y. Xie // J Mol Cell Biol. — 2010. — Vol. 2, No. 6. — P. 308−317.